Digestery
Longevity supplements › Rapamycin and Aging › Studies

Pooled review (meta-analysis)

In mice bred for Alzheimer's, pooled review of 13 studies: rapamycin improved maze performance

Cai and colleagues · Journal of Alzheimer's disease : JAD · 2024

Original title: Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-analysis of Preclinical Studies.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Rapamycin shortened the time mice needed to find the platform in a water maze by 15.60 seconds and raised platform crossings by 1.53 times.

The study at a glance

Type of study
Pooled review (meta-analysis)
Who or what was studied
13 studies · Mice bred to develop Alzheimer's disease
What was tested
Rapamycin vs no rapamycin in 13 animal studies
What it measured
Other health or performance measures
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Journal of Alzheimer's disease : JAD, 2024
Source
PubMed record 38640155. This page is based on the abstract only.

How much this study counts

  • ✓Pools the results of 13 studies.
  • •A pooled review is only as strong as the studies it pools.
  • •Measured other health measures, not aging and age-related decline itself.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a pooled review (meta-analysis), and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer

Other reviews on this question

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 1 field after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.